Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
This large international trial, conducted in 33 countries, showed that postoperative cisplatin-based chemotherapy improved overall survival among patients with completely resected non–small-cell lung cancer. The benefit was small but statistically significant. Small improvements in the survival rate...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-01, Vol.350 (4), p.351-360 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 4 |
| container_start_page | 351 |
| container_title | The New England journal of medicine |
| container_volume | 350 |
| creator | Arriagada, Rodrigo Bergman, Bengt Dunant, Ariane Le Chevalier, Thierry Pignon, Jean-Pierre Vansteenkiste, Johan |
| description | This large international trial, conducted in 33 countries, showed that postoperative cisplatin-based chemotherapy improved overall survival among patients with completely resected non–small-cell lung cancer. The benefit was small but statistically significant.
Small improvements in the survival rate stand to benefit many.
Worldwide, lung cancer accounts for the largest number of new cases of cancer and of deaths from cancer annually.
1
Complete surgical resection, whenever feasible, is generally recognized as the most effective initial treatment for non–small-cell lung cancer. Despite several randomized trials, adjuvant treatment has not been shown to benefit patients who have undergone complete resection, and prolonged adjuvant treatment with alkylating agents
2
or with radiotherapy
3
in patients with early-stage disease has even had deleterious effects on long-term survival. A meta-analysis
2
suggested that cisplatin-based adjuvant chemotherapy could yield an absolute overall survival advantage of 5 percent at five years. Several cooperative . . . |
| doi_str_mv | 10.1056/NEJMoa031644 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_586991</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>530301691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-a2caff4c34358fdc970345520c0ed92f75e550c30b0c1bbaba3bf19474ff97163</originalsourceid><addsrcrecordid>eNpt0ctu1DAUBmALgehQ2LFGEYIdAV_j8bJEhVINBXFZW45z3MngXGo7VLPjHXhDnqRGE7Us8MaW9fk_1jkIPSX4NcGienNxev5xNJiRivN7aEUEYyXnuLqPVhjTdcmlYkfoUYw7nBfh6iE6IlyySlG5Qpd1FydvUjeUb02Etjhpd_NPM6Si3kI_pi0EM-2Lbig-ZwRDisV1l7ZFPfaThwR-X3yBCDblpxfj8OfX76-98b6swftiMw-XRW0GC-ExeuCMj_Bk2Y_R93en3-qzcvPp_Yf6ZFNaIVUqDbXGOW4ZZ2LtWqskZlwIii2GVlEnBQiBLcMNtqRpTGNY44jikjunJKnYMSoPufEaprnRU-h6E_Z6NJ1ern7kE2ixrpQi2T8_-CmMVzPEpHfjHIb8RU0pUwKTSmb06oBsGGMM4G5jCdZ_h6D_HULmz5bMuemhvcNL1zN4uQATrfEu5BZ18c4JTmm1Ftm9OLi-j3qAXf__ejcAiZv1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223950167</pqid></control><display><type>article</type><title>Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer</title><source>MEDLINE</source><source>New England Journal of Medicine Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><creator>Arriagada, Rodrigo ; Bergman, Bengt ; Dunant, Ariane ; Le Chevalier, Thierry ; Pignon, Jean-Pierre ; Vansteenkiste, Johan</creator><creatorcontrib>Arriagada, Rodrigo ; Bergman, Bengt ; Dunant, Ariane ; Le Chevalier, Thierry ; Pignon, Jean-Pierre ; Vansteenkiste, Johan ; The International Adjuvant Lung Cancer Trial Collaborative Group ; International Adjuvant Lung Cancer Trial Collaborative Group</creatorcontrib><description>This large international trial, conducted in 33 countries, showed that postoperative cisplatin-based chemotherapy improved overall survival among patients with completely resected non–small-cell lung cancer. The benefit was small but statistically significant.
Small improvements in the survival rate stand to benefit many.
Worldwide, lung cancer accounts for the largest number of new cases of cancer and of deaths from cancer annually.
1
Complete surgical resection, whenever feasible, is generally recognized as the most effective initial treatment for non–small-cell lung cancer. Despite several randomized trials, adjuvant treatment has not been shown to benefit patients who have undergone complete resection, and prolonged adjuvant treatment with alkylating agents
2
or with radiotherapy
3
in patients with early-stage disease has even had deleterious effects on long-term survival. A meta-analysis
2
suggested that cisplatin-based adjuvant chemotherapy could yield an absolute overall survival advantage of 5 percent at five years. Several cooperative . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa031644</identifier><identifier>PMID: 14736927</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Carcinoma, Non-Small-Cell Lung - surgery ; Chemotherapy ; Chemotherapy, Adjuvant ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Clinical trials ; Disease-Free Survival ; Etoposide - administration & dosage ; Humans ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Lung Neoplasms - surgery ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Pharmacology. Drug treatments ; Pneumology ; Survival Rate ; Systematic review ; Tumors of the respiratory system and mediastinum ; Vinblastine - administration & dosage ; Vinblastine - analogs & derivatives ; Vindesine - administration & dosage</subject><ispartof>The New England journal of medicine, 2004-01, Vol.350 (4), p.351-360</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-a2caff4c34358fdc970345520c0ed92f75e550c30b0c1bbaba3bf19474ff97163</citedby><cites>FETCH-LOGICAL-c579t-a2caff4c34358fdc970345520c0ed92f75e550c30b0c1bbaba3bf19474ff97163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa031644$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223950167?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,776,780,881,2745,2746,26082,27903,27904,52361,54043,64362,64366,72216</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15422685$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14736927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:19868722$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Arriagada, Rodrigo</creatorcontrib><creatorcontrib>Bergman, Bengt</creatorcontrib><creatorcontrib>Dunant, Ariane</creatorcontrib><creatorcontrib>Le Chevalier, Thierry</creatorcontrib><creatorcontrib>Pignon, Jean-Pierre</creatorcontrib><creatorcontrib>Vansteenkiste, Johan</creatorcontrib><creatorcontrib>The International Adjuvant Lung Cancer Trial Collaborative Group</creatorcontrib><creatorcontrib>International Adjuvant Lung Cancer Trial Collaborative Group</creatorcontrib><title>Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>This large international trial, conducted in 33 countries, showed that postoperative cisplatin-based chemotherapy improved overall survival among patients with completely resected non–small-cell lung cancer. The benefit was small but statistically significant.
Small improvements in the survival rate stand to benefit many.
Worldwide, lung cancer accounts for the largest number of new cases of cancer and of deaths from cancer annually.
1
Complete surgical resection, whenever feasible, is generally recognized as the most effective initial treatment for non–small-cell lung cancer. Despite several randomized trials, adjuvant treatment has not been shown to benefit patients who have undergone complete resection, and prolonged adjuvant treatment with alkylating agents
2
or with radiotherapy
3
in patients with early-stage disease has even had deleterious effects on long-term survival. A meta-analysis
2
suggested that cisplatin-based adjuvant chemotherapy could yield an absolute overall survival advantage of 5 percent at five years. Several cooperative . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>Etoposide - administration & dosage</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Lung Neoplasms - surgery</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Survival Rate</subject><subject>Systematic review</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vindesine - administration & dosage</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0ctu1DAUBmALgehQ2LFGEYIdAV_j8bJEhVINBXFZW45z3MngXGo7VLPjHXhDnqRGE7Us8MaW9fk_1jkIPSX4NcGienNxev5xNJiRivN7aEUEYyXnuLqPVhjTdcmlYkfoUYw7nBfh6iE6IlyySlG5Qpd1FydvUjeUb02Etjhpd_NPM6Si3kI_pi0EM-2Lbig-ZwRDisV1l7ZFPfaThwR-X3yBCDblpxfj8OfX76-98b6swftiMw-XRW0GC-ExeuCMj_Bk2Y_R93en3-qzcvPp_Yf6ZFNaIVUqDbXGOW4ZZ2LtWqskZlwIii2GVlEnBQiBLcMNtqRpTGNY44jikjunJKnYMSoPufEaprnRU-h6E_Z6NJ1ern7kE2ixrpQi2T8_-CmMVzPEpHfjHIb8RU0pUwKTSmb06oBsGGMM4G5jCdZ_h6D_HULmz5bMuemhvcNL1zN4uQATrfEu5BZ18c4JTmm1Ftm9OLi-j3qAXf__ejcAiZv1</recordid><startdate>20040122</startdate><enddate>20040122</enddate><creator>Arriagada, Rodrigo</creator><creator>Bergman, Bengt</creator><creator>Dunant, Ariane</creator><creator>Le Chevalier, Thierry</creator><creator>Pignon, Jean-Pierre</creator><creator>Vansteenkiste, Johan</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20040122</creationdate><title>Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer</title><author>Arriagada, Rodrigo ; Bergman, Bengt ; Dunant, Ariane ; Le Chevalier, Thierry ; Pignon, Jean-Pierre ; Vansteenkiste, Johan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-a2caff4c34358fdc970345520c0ed92f75e550c30b0c1bbaba3bf19474ff97163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>Etoposide - administration & dosage</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Lung Neoplasms - surgery</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Survival Rate</topic><topic>Systematic review</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vindesine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arriagada, Rodrigo</creatorcontrib><creatorcontrib>Bergman, Bengt</creatorcontrib><creatorcontrib>Dunant, Ariane</creatorcontrib><creatorcontrib>Le Chevalier, Thierry</creatorcontrib><creatorcontrib>Pignon, Jean-Pierre</creatorcontrib><creatorcontrib>Vansteenkiste, Johan</creatorcontrib><creatorcontrib>The International Adjuvant Lung Cancer Trial Collaborative Group</creatorcontrib><creatorcontrib>International Adjuvant Lung Cancer Trial Collaborative Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arriagada, Rodrigo</au><au>Bergman, Bengt</au><au>Dunant, Ariane</au><au>Le Chevalier, Thierry</au><au>Pignon, Jean-Pierre</au><au>Vansteenkiste, Johan</au><aucorp>The International Adjuvant Lung Cancer Trial Collaborative Group</aucorp><aucorp>International Adjuvant Lung Cancer Trial Collaborative Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-01-22</date><risdate>2004</risdate><volume>350</volume><issue>4</issue><spage>351</spage><epage>360</epage><pages>351-360</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>This large international trial, conducted in 33 countries, showed that postoperative cisplatin-based chemotherapy improved overall survival among patients with completely resected non–small-cell lung cancer. The benefit was small but statistically significant.
Small improvements in the survival rate stand to benefit many.
Worldwide, lung cancer accounts for the largest number of new cases of cancer and of deaths from cancer annually.
1
Complete surgical resection, whenever feasible, is generally recognized as the most effective initial treatment for non–small-cell lung cancer. Despite several randomized trials, adjuvant treatment has not been shown to benefit patients who have undergone complete resection, and prolonged adjuvant treatment with alkylating agents
2
or with radiotherapy
3
in patients with early-stage disease has even had deleterious effects on long-term survival. A meta-analysis
2
suggested that cisplatin-based adjuvant chemotherapy could yield an absolute overall survival advantage of 5 percent at five years. Several cooperative . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>14736927</pmid><doi>10.1056/NEJMoa031644</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-01, Vol.350 (4), p.351-360 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_586991 |
| source | MEDLINE; New England Journal of Medicine Current; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - radiotherapy Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Chemotherapy, Adjuvant Cisplatin - administration & dosage Cisplatin - adverse effects Clinical trials Disease-Free Survival Etoposide - administration & dosage Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Lung Neoplasms - surgery Medical sciences Middle Aged Neoplasm Staging Pharmacology. Drug treatments Pneumology Survival Rate Systematic review Tumors of the respiratory system and mediastinum Vinblastine - administration & dosage Vinblastine - analogs & derivatives Vindesine - administration & dosage |
| title | Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A58%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cisplatin-Based%20Adjuvant%20Chemotherapy%20in%20Patients%20with%20Completely%20Resected%20Non%E2%80%93Small-Cell%20Lung%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Arriagada,%20Rodrigo&rft.aucorp=The%20International%20Adjuvant%20Lung%20Cancer%20Trial%20Collaborative%20Group&rft.date=2004-01-22&rft.volume=350&rft.issue=4&rft.spage=351&rft.epage=360&rft.pages=351-360&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa031644&rft_dat=%3Cproquest_swepu%3E530301691%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223950167&rft_id=info:pmid/14736927&rfr_iscdi=true |